KIAA0895 Inhibitors
KIAA0895 inhibitors encompass a diverse array of compounds that indirectly restrict the protein's activity through interference with specific signaling pathways or biological processes. Rapamycin, for example, is a potent mTOR inhibitor which suppresses cellular proliferation, potentially diminishing KIAA0895 activity by limiting the cellular conditions necessary for its function, given that KIAA0895 is implicated in cell cycle-related processes. Similarly, LY294002 and Wortmannin are PI3K inhibitors that disrupt the PI3K/AKT pathway, integral for cell survival and growth. The inhibition of this pathway likely decreases KIAA0895 activity if it is involved in these or analogous cellular functions. Triciribine, by preventing AKT phosphorylation, and U0126 and PD98059, as MEK inhibitors, also contribute to the modulation of signaling cascades that could indirectly influence KIAA0895 functions, assuming involvement in cell division or differentiation pathways.
Further, SP600125 and SB203580, which inhibit JNK and p38 MAPK respectively,could modify the cellular stress response mechanisms possibly engaging KIAA0895. Y-27632's role as a ROCK inhibitor affects cytoskeleton organization, which could impinge on KIAA0895 if it plays a part in cytoskeletal dynamics. Bortezomib, by inhibiting proteasome activity, could alter the degradation rate of proteins, including possibly KIAA0895, if it is subject to ubiquitin-proteasome-mediated turnover. Thapsigargin and Tunicamycin disrupt calcium homeostasis and N-linked glycosylation, respectively; these processes, when inhibited, might impede KIAA0895's activity if it is implicated in calcium signaling or relies on glycosylation for its stability or localization. Collectively, these inhibitors operate through distinct yet interconnected biochemical pathways, converging on the indirect inhibition of KIAA0895, with each compound contributing to the modulation of the protein's activity in a specific and unique manner.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress cellular proliferation and consequently reduce the activity of proteins involved in cell cycle progression. As KIAA0895 is implicated in cellular processes, inhibition of mTOR could indirectly reduce KIAA0895 activity by limiting cellular conditions necessary for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that disrupts the PI3K/AKT pathway, which is crucial for many cellular processes including survival and growth. By inhibiting this pathway, LY294002 could indirectly decrease the functional activity of KIAA0895 if it is involved in similar cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that operates in a similar fashion to LY294002, but with a different binding mechanism. This compound would also lead to a decreased activity of KIAA0895 by disrupting signaling pathways it may be involved in. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
An AKT inhibitor that prevents the phosphorylation and activation of AKT, thereby affecting downstream signaling pathways. If KIAA0895 functions downstream of AKT, its activity would be indirectly inhibited. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that interrupts the MAPK/ERK pathway. Since this pathway is involved in cell division and differentiation, KIAA0895 activity could be indirectly limited through the inhibition of MEK. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Similar to U0126, PD98059 is a MEK inhibitor that could lead to decreased activity of KIAA0895 by blocking the MAPK/ERK signaling, if KIAA0895 is part of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, part of the MAPK family. By inhibiting JNK, SP600125 could reduce KIAA0895 activity indirectly by modulating the cellular environment and stress response pathways that it may be associated with. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could indirectly affect KIAA0895 activity by altering signal transduction processes and cellular responses to stress, if KIAA0895 is implicated in these pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that modulates cytoskeleton organization and cellular contractility. Inhibition of ROCK could lead to reduced KIAA0895 activity if it is implicated in pathways involving cytoskeletal dynamics. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can affect the degradation of cellular proteins, potentially including KIAA0895. By preventing protein degradation, bortezomib may indirectly reduce the functional activity of KIAA0895 if it is regulated by the ubiquitin-proteasome system. | ||||||